🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

What happens when you query chatGPT with 362 breast cancer cases? -46% responses differed from breast cancer expert opinion -when the same case was entered 3 times, the responses differed ~2/3 of the time ! -for examples, see 🧵..

Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Clinical Insights ascopubs.org/doi/10.1200/OP…

After a CDK4/6 Inhibitor: State of the Art in Hormone Receptor–Positive Metastatic Breast Cancer ascopubs.org/doi/pdf/10.120…

After saying goodbye to anthracyclines— are we ready to also drop the carbo for our patients with stage II HER2+ breast cancer? Check out this discussion with friends and superstar breast oncs Yara Abdou, MD, MSCR Jason A. Mouabbi MD — powered by OncLive.com

DESTINY-Breast09: First-line T-DXd + pertuzumab significantly prolongs PFS vs THP in HER2+ mBC: 40.7 vs 26.9 mo (HR 0.56; P<.00001)‼️ New first-line standard? Led by Sara Tolaney and discussed by Claudine Isaacs at #ASCO25 #BreastCancer ➡️ascopost.com/issues/june-25…

I was so excited to join VJ Oncology at #ASCO25 with MD Anderson Cancer Center to dig into neoadjuvant endocrine therapy vs. chemo in Stage II/III ER+/HER2– lobular carcinoma! 🌟 🎥 I promise, it’s a quick watch with my top takeaways and why this matters for #ILC patients. 👉 Tune in and

Even CDK4/6 inhibitors can have uncommon side effects like vitiligo. #mascc25

🩸Iron Deficiency for the Practicing Oncologist JCO Oncology Practice ✅A very useful excellent review 👉ascopubs.org/doi/pdf/10.120… ASCO #cancer #oncology #MedX OncoAlert Top Biomedical Science Top Science

For dMMR colon cancer, FOLFOX + atezolizumab per ATOMIC is now incorporated into the NCCN Guidelines. Mayo Clinic Comprehensive Cancer Center Alliance for Clinical Trials in Oncology The ASCO Post Colorectal Cancer Alliance Cure GI Cancers Fight Colorectal Cancer

Evaluation and Treatment of Iron Deficiency for the Practicing Oncologist | JCO Oncology Practice ascopubs.org/doi/10.1200/OP… JCO Oncology Practice ASCO Journal of Clinical Oncology OncoAlert

Fantastic power summary by Dr Mothaffar Rimawi on HER2+ Breast Cancer and lessons learnt from recent trials. #bcsm BCMHouston BCM Clinician Resources Dan L Duncan Comprehensive Cancer Center BCMCancerEd

🎗️ 20 Years of Progress in Lung Adenocarcinoma New real-world data from France show a remarkable 📊 From 16.3% to 38.6% 3-year OS #Oncology #LungCancer #Immunotherapy #TargetedTherapy #RealWorldData #NEJM #KBPStudy #CancerResearch #Survival #Infographic NEJM

Adverse events in patients treated with neoadjuvant chemo/immunotherapy for triple negative breast cancer: results from seven academic medical centers link.springer.com/article/10.100… In this large real-world study of 415 patients with early-stage or locally advanced triple-negative

Last but not least - Erika Hamilton, MD closes the session with her fun spin on Exciting New Therapies for MBC. An impressive pipeline of innovative agents, attacking breast cancer from all sides: PROTACs, bispecific antibodies, B7H4 ADCs, mutant selective PI3Ki… and more! #IBCE25

📌 Genomic landscape of hormone therapy‑resistant HR‑positive, HER2‑negative breast cancer 🧬 What drives hormone therapy resistance in HR+/HER2− breast cancer? A new study dives deep into genomics, clonal evolution, and the role of ctDNA in predicting relapse. 🔗

Deep learning-based quantification of TILs as a prognostic indicator in nasopharyngeal carcinoma: multicohort findings in ESMO Open. DL-assessed TILs strongly correlates with survival in NPC, better prediction than IHC. esmoopen.com/article/S2059-…

Check out this recent paper on #InflammatoryBreastCancer, it examines the clinicogenomic characterization of #IBC. 👉pubmed.ncbi.nlm.nih.gov/40378057/ @npriedig Brittany Bychkovsky, MD jennifer bellon Tari King MD Eric Winer, MD Lynette Sholl Sara Tolaney Nancy Lin, MD Filipa Lynce, MD, FASCO 🇵🇹 🇺🇸 Romualdo Barroso, MD PhD

CDK4/6 Inhibition Beyond Progression in postMONARCH: Are We Seeing the Full Picture? 💥A great editorial offering a critical look at the use of CDK4/6 inhibitors beyond progression, exploring methodological uncertainties and implications for clinical practice.

Expected pathological complete response rates in early stage II/III HER2+ breast cancer. #bcsm Dana-Farber’s Breast Oncology Center

Follow-up results from the POSITIVE Trial regarding breastfeeding after hormone receptor-positive #BreastCancer show no differences in breast cancer related events in women who breastfed compared with those who did not. 👉pubmed.ncbi.nlm.nih.gov/40632989/ Fedro Peccatori MD, PhD Ann Partridge MD, MPH